Update on prostate-specific antigen testing for the early detection of prostate cancer

John D. Terrell, Claus Roehrborn, Frank H. Wians, Pierre I. Karakiewicz, Shahrokh F. Shariat

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The introduction of prostate-specific antigen (PSA) has revolutionized the detection and management of men with prostate cancer (PCa). This review discusses the clinically useful risk factors associated with the development of PCa and the salient features of PSA. It will help to highlight the abilities and limitations of PSA with respect to the diagnosis and management of PCa. Emphasis will be placed on the factors affecting serum total PSA (tPSA) levels, the optimal cutoff values, the use of calculated parameters such as PSA density, PSA transition zone density, PSA velocity, age- and race-specific PSA ranges, and the various molecular forms. There is an imminent need for novel biomarkers that can improve specificity for PCa, allow accurate classification of clinically insignificant PCa, allow for detection of clinically significant PCa in patients without elevated serum PSA, and allow for the identification of aggressive forms of PCa, which may warrant adjunctive or even molecularly targeted therapy in the future.

Original languageEnglish (US)
Pages (from-to)613-621
Number of pages9
JournalLaboratory Medicine
Volume39
Issue number10
DOIs
StatePublished - 2008

Fingerprint

Prostate-Specific Antigen
Early Detection of Cancer
Prostatic Neoplasms
Testing
Biomarkers
Serum

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Update on prostate-specific antigen testing for the early detection of prostate cancer. / Terrell, John D.; Roehrborn, Claus; Wians, Frank H.; Karakiewicz, Pierre I.; Shariat, Shahrokh F.

In: Laboratory Medicine, Vol. 39, No. 10, 2008, p. 613-621.

Research output: Contribution to journalArticle

Terrell, John D. ; Roehrborn, Claus ; Wians, Frank H. ; Karakiewicz, Pierre I. ; Shariat, Shahrokh F. / Update on prostate-specific antigen testing for the early detection of prostate cancer. In: Laboratory Medicine. 2008 ; Vol. 39, No. 10. pp. 613-621.
@article{fb9d3a35426b45cd8ea900c513f9509d,
title = "Update on prostate-specific antigen testing for the early detection of prostate cancer",
abstract = "The introduction of prostate-specific antigen (PSA) has revolutionized the detection and management of men with prostate cancer (PCa). This review discusses the clinically useful risk factors associated with the development of PCa and the salient features of PSA. It will help to highlight the abilities and limitations of PSA with respect to the diagnosis and management of PCa. Emphasis will be placed on the factors affecting serum total PSA (tPSA) levels, the optimal cutoff values, the use of calculated parameters such as PSA density, PSA transition zone density, PSA velocity, age- and race-specific PSA ranges, and the various molecular forms. There is an imminent need for novel biomarkers that can improve specificity for PCa, allow accurate classification of clinically insignificant PCa, allow for detection of clinically significant PCa in patients without elevated serum PSA, and allow for the identification of aggressive forms of PCa, which may warrant adjunctive or even molecularly targeted therapy in the future.",
author = "Terrell, {John D.} and Claus Roehrborn and Wians, {Frank H.} and Karakiewicz, {Pierre I.} and Shariat, {Shahrokh F.}",
year = "2008",
doi = "10.1309/LM6C66PTQDSPJQET",
language = "English (US)",
volume = "39",
pages = "613--621",
journal = "Laboratory Medicine",
issn = "0007-5027",
publisher = "American Society of Clinical Pathologists",
number = "10",

}

TY - JOUR

T1 - Update on prostate-specific antigen testing for the early detection of prostate cancer

AU - Terrell, John D.

AU - Roehrborn, Claus

AU - Wians, Frank H.

AU - Karakiewicz, Pierre I.

AU - Shariat, Shahrokh F.

PY - 2008

Y1 - 2008

N2 - The introduction of prostate-specific antigen (PSA) has revolutionized the detection and management of men with prostate cancer (PCa). This review discusses the clinically useful risk factors associated with the development of PCa and the salient features of PSA. It will help to highlight the abilities and limitations of PSA with respect to the diagnosis and management of PCa. Emphasis will be placed on the factors affecting serum total PSA (tPSA) levels, the optimal cutoff values, the use of calculated parameters such as PSA density, PSA transition zone density, PSA velocity, age- and race-specific PSA ranges, and the various molecular forms. There is an imminent need for novel biomarkers that can improve specificity for PCa, allow accurate classification of clinically insignificant PCa, allow for detection of clinically significant PCa in patients without elevated serum PSA, and allow for the identification of aggressive forms of PCa, which may warrant adjunctive or even molecularly targeted therapy in the future.

AB - The introduction of prostate-specific antigen (PSA) has revolutionized the detection and management of men with prostate cancer (PCa). This review discusses the clinically useful risk factors associated with the development of PCa and the salient features of PSA. It will help to highlight the abilities and limitations of PSA with respect to the diagnosis and management of PCa. Emphasis will be placed on the factors affecting serum total PSA (tPSA) levels, the optimal cutoff values, the use of calculated parameters such as PSA density, PSA transition zone density, PSA velocity, age- and race-specific PSA ranges, and the various molecular forms. There is an imminent need for novel biomarkers that can improve specificity for PCa, allow accurate classification of clinically insignificant PCa, allow for detection of clinically significant PCa in patients without elevated serum PSA, and allow for the identification of aggressive forms of PCa, which may warrant adjunctive or even molecularly targeted therapy in the future.

UR - http://www.scopus.com/inward/record.url?scp=59849107949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849107949&partnerID=8YFLogxK

U2 - 10.1309/LM6C66PTQDSPJQET

DO - 10.1309/LM6C66PTQDSPJQET

M3 - Article

AN - SCOPUS:59849107949

VL - 39

SP - 613

EP - 621

JO - Laboratory Medicine

JF - Laboratory Medicine

SN - 0007-5027

IS - 10

ER -